HomeHealth TopicsImmune SystemMyelodysplastic Syndromes
Back to Immune System
Myelodysplastic Syndromes
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Immune System

Myelodysplastic Syndromes

Myelodysplastic syndromes are rare conditions where bone marrow stem cells fail to mature into healthy blood cells, often leading to anemia, infection, or bleeding.

Understanding the Condition

Bone marrow is the spongy tissue found inside bones, such as the hip and thigh. It houses stem cells, which develop into three vital types of blood cells: red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which assist in clotting). In patients with myelodysplastic syndromes, these stem cells do not mature properly and many die within the bone marrow, resulting in a shortage of healthy blood cells.

Symptoms

These syndromes often lack early symptoms and may be discovered during routine blood tests. When symptoms do occur, they may include:

  • Shortness of breath
  • Weakness or fatigue
  • Pale skin
  • Easy bruising or bleeding
  • Pinpoint spots under the skin caused by bleeding
  • Fever or frequent infections

Risk Factors and Treatment

Myelodysplastic syndromes are rare. Individuals at higher risk include those over 60, those who have undergone chemotherapy or radiation therapy, or those exposed to certain chemicals. Treatment options include:

  • Transfusions
  • Drug therapy
  • Chemotherapy
  • Blood or bone marrow stem cell transplants

Frequently Asked Questions

While they won’t cure the marrow defect, certain measures can improve quality of life: maintain a balanced diet with iron‑rich foods (if anemia is present) and vitamin K‑containing foods (if platelet counts allow) to support clotting; stay hydrated; engage in light‑to‑moderate activity as tolerated to combat fatigue; and avoid medications that further suppress platelets (e.g., NSAIDs) unless prescribed. Discuss any supplements with your hematology team to prevent interactions.
Prognosis varies widely and is calculated using scoring systems (e.g., IPSS‑R) that consider bone‑marrow blast percentage, cytogenetics, and blood counts. Low‑risk MDS may have a median survival of 5‑10 years with supportive care, while high‑risk disease can progress to acute myeloid leukemia within months to a few years. Your hematologist will provide a personalized risk estimate.
llogeneic stem‑cell transplantation is the only potentially curative option and is usually offered to patients with intermediate‑ or high‑risk MDS who are fit enough for the procedure (generally age < 70 years and adequate organ function). A comprehensive evaluation of comorbidities, donor availability, and disease genetics determines eligibility.
fter initiating therapy, complete blood counts are typically checked every 1‑2 weeks until stability, then every 1‑3 months. A repeat bone‑marrow biopsy is usually performed 3‑6 months after starting disease‑modifying treatment (e.g., hypomethylating agents) to assess response and guide further therapy.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss